{"nctId":"NCT00445939","briefTitle":"A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease","startDateStruct":{"date":"2007-02"},"conditions":["Crohn's Disease"],"count":90,"armGroups":[{"label":"Adalimumab 160 mg/80 mg","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]},{"label":"Adalimumab 80 mg/40 mg","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: placebo"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Crohn's Disease Activity Index (CDAI) score of \\>= 220 and \\<= 450\n* If subjects have previously been administered infliximab, subjects who discontinued use due to a loss of response or intolerance to infliximab therapy\n\nExclusion Criteria:\n\n* Ulcerative colitis or indeterminate colitis\n* History of cancer, lymphoma, leukemia or lymphoproliferative disease, active tuberculosis (TB), or Human immunodeficiency virus (HIV)\n* Body weight is below 30 kg\n* Surgical bowel resections within the past 6 months\n* Females who are pregnant or breast-feeding or considering becoming pregnant during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4","description":"CDAI is used to quantify the symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Comparison of the number of subjects with a clinical remission (CDAI \\< 150) in the adalimumab 160 mg (Week 0)/ 80 mg (Week 2) and adalimumab 80 mg (Week 0)/ 40 mg (Week 2) groups at Week 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Remission (CDAI < 150) at Week 2","description":"Number of subjects in each treatment group in clinical remission (CDAI \\< 150) in Full Analysis Set (FAS) using non-responder Imputation (NRI) at Week 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response (CR-70 and CR-100) in Period A","description":"The number of subjects in each treatment group with a clinical response 70 (CDAI decrease of \\>=70 compared to Baseline) and 100 (CDAI decrease of \\>=100 compared to Baseline) at Week 2 and Week 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response (CR-70 and CR-100) in Period B","description":"The Number of subjects in each treatment group with a CR-70 (CDAI decrease of \\>= 70 compared to Baseline) and 100 (CDAI decrease of \\>= 100 compared to Baseline) in subjects who were non-responders at Week 4 at Week 6 and Week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Remission (CDAI <150) at Week 6 and Week 8","description":"The number of subjects with clinical remission (CDAI \\< 150) in the subjects who were non-responders at Week 4 calculated with non-responder imputation (NRI) at Week 6 and Week 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Injection site reaction","Nasopharyngitis","Upper respiratory tract infection","Nausea"]}}}